The Chemours Company Reports Third Quarter Results
Wilmington, Del.,November 2, 2026 – The Chemours Company (“Chemours” or “the Company”) (NYSE: CC), a global chemistry company with leading market positions in Thermal & Specialized Solutions (“TSS”), Titanium Technologies (“TT”), and Advanced Performance Materials (“APM”), today announced its financial results for the third quarter 2026.
Key Third Quarter 2026 Results & Recent Highlights1 Net Sales of $1.5 billion, up slightly from the prior-year quarter, reflecting an approximately 10% year-over-year pricing increase in TT and 26% year-over- year growth in APM Performance Solutions.
Net Income attributable to Chemours of $196 million, or $1.29 per diluted share, compared with Net Income attributable to Chemours of $46 million, or $0.31 per diluted share, in the corresponding prior-year quarter.
Adjusted Net Income 2 of $31 million, or $0.21 per diluted share, compared with Adjusted Net Income of $26 million, or $0.17 per diluted share, in the corresponding prior-year quarter.
Adjusted EBITDA 2,3 of $200 million, compared with $189 million in the prior- year quarter, driven by improved pricing in TT and growth in APM Performance Solutions.
As previously announced, entered into a settlement with the State of North Carolina and 11 local entities to resolve litigation relating to PFAS and other historical discharges from Fayetteville Works, as well as claims of PFAS contamination unrelated to that site, including from the use of AFFF.
Formally launching Chemours’ liquid cooling portfolio, including four two-phase direct-to-chip and one immersion cooling fluid under the Faizeon™ liquid cooling brand.
Completed the sale of the Kuan Yin property for total net consideration of ~$340 million, including the remaining land parcel for $56 million of gross proceeds. “Our third-quarter results demonstrate strong year-over-year performance in TT and APM, reflecting pricing execution in TiO2and increased demand across Performance Solutions’ high-value AI infrastructure including data center and semiconductor end markets,” said Denise Dignam, Chemours President and CEO. “We also continued to make meaningful progress under our Pathway to Thrive, including reaching a settlement with the State of North Carolina, driving operational improvements through the Chemours Business System, and closing the sale of the final parcel of land associated with our former Kuan Yin property. While we continue to navigate TSS stationary aftermarket dynamics and a softer macroeconomic environment, we remain focused on disciplined execution of our strategic priorities and the factors within our control to drive long-term returns for shareholders.”
1Certain prior period amounts have been revised to correct for certain immaterial errors as further described in our Annual Report on Form 10-K for the year ended December 31, 2025 as well as the 2025 Earnings Presentation.
2Non-GAAP measures, including Adjusted Net Income, Adjusted EPS and Adjusted EBITDA referred to throughout, principally exclude the impact of recent litigation settlements for legacy environmental matters and associated fees, in addition to other unallocated items – please refer to the attached "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)”.
3Adjusted EBITDA excludes net income attributable to noncontrolling interests, net interest expense, depreciation and amortization, and all remaining provision for income taxes from Adjusted Net Income. See the corresponding reconciliation referenced in footnote #2.
4Restricted cash approximated $103 million of the end of the third quarter of 2026, reflected primarily the PFAS Insurance Escrow and will be further described in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. EXHIBIT 99.1 Total Chemours
Third quarter 2026 Net Sales were approximately $1.5 billion, an increase of approximately 3% compared with the prior-year quarter. The year-over-year increase in Net Sales was driven by a 5% increase in pricing, partially offset by a 2% decrease in volumes and a slight currency headwind. The pricing increase was primarily driven by previously announced price actions in TT, complemented by a favorable mix shift toward APM Performance Solutions. Lower year-over-year volumes primarily reflected anticipated lower North American stationary AC aftermarket sales of TSS Opteon TM blends compared with elevated demand in the prior-year quarter. Third quarter 2026 Net Income attributable to Chemours was $196 million, or $1.29 per diluted share, compared with $46 million, or $0.31 per diluted share, in the prior-year quarter. Current-year third-quarter Net Income included the receipt of $150 million related to the PFAS insurance proceeds MOU that was executed in connection with the finalization of the judicial consent order ("JCO") with the State of New Jersey. This was presented as a reduction to Selling, general, and administrative expense. Third quarter Adjusted Net Income increased 19% compared with the prior-year quarter, aligned with trends in Adjusted EBITDA as highlighted below. Adjusted EBITDA for the third quarter of 2026 was $200 million, compared with $189 million in the prior- year quarter. The increase was driven by pricing momentum in TT and a favorable mix shift toward APM Performance Solutions, partially offset by lower TSS volumes associated with the North American stationary AC aftermarket dynamics noted above and higher costs across each business. 2On a diluted earnings per share basis. EXHIBIT 99.1 Thermal & Specialized Solutions
TSS segment third quarter 2026 Net Sales were $510 million, a decrease of 9% compared with the prior-year quarter, driven by a 9% decrease in volumes and a slight decrease in price. The decrease in volumes was primarily attributable to lower North American stationary AC aftermarket sales of TSS Opteon™ blends compared with elevated demand in the prior-year quarter, which benefited from the initial aftermarket channel fill associated with the stationary AC technology transition under the U.S. AIM Act. Adjusted EBITDA for the quarter decreased 30% to $136 million, while Adjusted EBITDA Margin decreased eight points to 27%. The decrease in Adjusted EBITDA was primarily driven by the lower Opteon TM stationary aftermarket sales noted above and higher costs incurred during the period. Sequentially, TSS Net Sales decreased 14%, driven by lower volumes associated with seasonal demand trends in the North American stationary AC aftermarket, as well as a slight currency headwind, partially offset by pricing. Titanium Technologies
TT segment third quarter 2026 Net Sales were $680 million, an 11% increase compared with the prior-year quarter. The increase was driven by a 10% increase in global pricing and a 1% increase in global volumes, partially offset by a slight currency headwind. Pricing increased across all regions in connection with recent pricing announcements, while global volume growth reflected strength in North America, Latin America, and APAC excluding China that more than offset lower volumes across EMEA and China. TT segment third quarter 2026 Adjusted EBITDA increased to $85 million from $25 million in the prior-year quarter and Adjusted EBITDA Margin increased by nine points to 13%. The increase in Adjusted EBITDA was primarily driven by the global pricing strength noted above and higher volumes, partially offset by modest cost inflation. Sequentially, TT segment third quarter 2026 Net Sales increased 3%, driven by a 4% increase in price, reflecting continued execution of recent TiO 2 pricing announcements, partially offset by a 1% decrease in global volumes and a slight currency headwind. 2On a diluted earnings per share basis. EXHIBIT 99.1 Advanced Performance Materials
APM segment third quarter 2026 Net Sales were $337 million, an 8% increase compared with the prior-year quarter. The increase was driven by a 6% increase in price and a 2% increase in volume, partially offset by a slight currency headwind. Performance Solutions Net Sales increased 26%, reflecting continued order book strength and momentum in high-value specialty products serving data center and semiconductor end markets. APM segment third quarter 2026 Adjusted EBITDA increased 71% to $24 million compared with the prior-year quarter, while Adjusted EBITDA Margin increased two points to 7%. The increase in Adjusted EBITDA was primarily driven by a favorable mix shift toward higher-value Performance Solutions products serving data center and semiconductor end markets, partially offset by higher costs incurred during the period. Sequentially, APM segment third quarter 2026 Net Sales increased approximately 3%, driven by a 2% increase in price and a 1% increase in volume. Performance Solutions Net Sales increased 8%, reflecting continued order book strength and momentum in high-value specialty products serving data center and semiconductor end markets. EXHIBIT 99.1 Other Non-Reportable Segment
The Performance Chemicals and Intermediates business in the Company’s Other Non- Reportable Segment had Net Sales and Adjusted EBITDA for the third quarter 2026 of $13 million and $1 million, respectively.
Corporate Expenses were $46 million in the third quarter of 2026, an increase of approximately $1 million compared with the prior-year quarter.
As of September 30, 2026, consolidated gross debt was $3.9 billion. Debt, net of $698 million in unrestricted4cash and cash equivalents, was $3.2 billion, resulting in a Net Leverage ratio of approximately 4.3x on a trailing twelve- month Adjusted EBITDA basis. Total liquidity was $1.7 billion, composed of $698 million in unrestrictedcash and cash equivalents and $953 million of revolving credit facility capacity, net of outstanding letters of credit.
Operating cash flows for the third quarter of 2026 were $149 million, which includes the aforementioned receipt of $150 million in restricted cash related to the PFAS insurance proceeds MOU in connection with the finalization of the JCO with the State of New Jersey, partially offset by an approximately $100 million use of restricted cash to fund settlement payments associated with the 2025 settlement with the State of New Jersey and approximately $25 million of taxes related to the property sale in Kuan Yin. This is compared with $146 million of operating cash flows in the prior-year quarter. Capital expenditures for the third quarter of 2026 amounted to $51 million, an increase compared with $41 million in the prior-year quarter.
Free Cash Flows for the third quarter of 2026 were $98 million, compared with $105 million in the third quarter of 2025.
3Restricted cash was $103 million at the end of the third quarter of 2026, primarily reflecting PFAS Insurance proceeds MOU escrow recorded during the quarter as further described in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. EXHIBIT 99.1 Fourth Quarter 2026 Outlook In the fourth quarter, the Company expects consolidated Net Sales to decrease in the range of 5% to 10%, sequentially, driven by seasonality in TSS and TT, with consolidated Adjusted EBITDA expected to range between $160 million and $185 million. Corporate Expenses are expected to be approximately $40 million to $45 million. The Company also anticipates capital expenditures to be between $75 million and $85 million, with positive Free Cash Flows.
TSS expects Net Sales will sequentially decrease in the high-teens to low- twenties percentage range, driven by traditional seasonal patterns related to the North American cooling season. Adjusted EBITDA is expected to be between $105 million and $115 million.
TT expects a sequential Net Sales decrease in the high single-digit to low-teens percentage range, driven by seasonality. Adjusted EBITDA is expected to range between $60 million and $65 million.
APM expects a sequential Net Sales increase in the low-to-mid teens percentage range, driven by order book strength for Performance Solutions products and certain customer contractual obligations benefiting the fourth quarter. Adjusted EBITDA for APM is expected to be between $40 million and $45 million. Full Year 2026 Outlook The Company expects 2026 Net Sales to grow approximately 2% over 2025, with Adjusted EBITDA between $775 million and $800 million. Capital expenditures are anticipated to be between $220 million and $230 million, with overall Free Cash Flow Conversion above 15%, which includes receipt of $150 million in restricted cash related to the PFAS insurance proceeds MOU in connection with the finalization of the JCO with the State of New Jersey, partially offset by legal settlement payments in the year related to the finalization of the JCO with the State of New Jersey and the announced settlement with the State of North Carolina during the third quarter of 2026 as well as the taxes associated with the Kuan Yin property sale now complete. The Company now anticipates achieving a Net Leverage ratio below 4.2x in 2026. EXHIBIT 99.1 Conference Call
As previously announced, Chemours will hold a conference call and webcast on November 3, 2026, at 8:00 a.m. Eastern Standard Time. The webcast and materials can be accessed by visiting theEvents & Presentationspage of Chemours’ investor website,investors.chemours.com. A webcast replay of the conference call will be available on Chemours’ investor website.
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemical products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers’ biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware, and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visitchemours.comor follow us onLinkedIn.
We prepare our financial statements in accordance with Generally Accepted Accounting Principles (GAAP). Within this press release, we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Free Cash Flows, Free Cash Flow Conversion, Total Debt Principal, Net and Net Leverage Ratio which are non-GAAP financial measures. The Company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Management uses Adjusted Net Income, Adjusted EPS and Adjusted EBITDA, which adjust for (i) certain non-cash items, (ii) certain items we believe are not indicative of ongoing operating performance, or (iii) certain nonrecurring, unusual or infrequent items to evaluate the Company's performance in order to have comparable financial results to analyze changes in our underlying business from period to period. Additionally, Free Cash Flows, Free Cash Flow Conversion, Total Debt Principal, Net and Net Leverage Ratio are utilized as liquidity measures to assess the cash generation of our businesses and ongoing liquidity position.
Accordingly, the Company believes the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the Company's operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. This analysis, as well as the other information in this press release, should be read in conjunction with the Company's financial statements and footnotes contained in the documents that the Company files with the U.S. Securities and Exchange Commission. The non-GAAP financial measures used by the Company in this press release may be different from the methods used by other companies. The Company does not provide a reconciliation of certain forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For more information on the non-GAAP financial measures, please refer to the attached schedules or the table, "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)" and materials posted to the Company's website at investors.chemours.com. EXHIBIT 99.1 Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, guidance on Company and segment performance for the fourth quarter of 2026, the full year 2026 and the Company’s corporate strategy. Forward- looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward- looking statements also involve risks and uncertainties including the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, our ability to maintain an effective internal control over financial reporting and disclosure controls and procedures, changes in environmental regulations in the United States or other jurisdictions that affect demand for or adoption of our products, changes in regulations in the United States or other jurisdictions that could impose tariffs or additional costs on products we either sell or need to purchase, anticipated future operating and financial performance for our segments individually and our company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, efforts to resolve outstanding or potential litigation, including claims related to legacy PFAS liabilities, plans for dividends, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, ourability todevelop and commercialize new products or technologies and obtain necessary regulatory approvals,our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements also may involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions, global conflicts, changes in laws and regulations in the United States or other jurisdictions in which we operate, and global health events and weather events, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our forthcoming Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 and the Annual Report on Form 10-K for the year ended December 31, 2025. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law. EXHIBIT 99.1 CONTACTS:
INVESTORSBrandon OntjesVice President, Head of Strategy & Investor Relations+1.302.773.3309
NEWS MEDIACassie OlszewskiMedia Relations & Reputation [email protected] The Chemours Company Consolidated Statements of Operations (Unaudited) 1 (Dollars in millions, except per share amounts)
(1) Selling, general, and administrative expense for the three and nine months ended September 30, 2026 includes $150 million received by the Company related to the PFAS Insurance proceeds MOU. Further details will be included in "Note 17 - Commitments and Contingent Liabilities" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.
The Chemours Company Consolidated Balance Sheets (Unaudited) 1 (Dollars in millions, except per share amounts)
September 30, 2026 December 31, 2025 ────────────────────────────────────────────────────────────────────────────── Assets Current assets: Cash and cash $ 698 $ 670 equivalents Restricted cash and restricted cash 41 2 equivalents Accounts and notes 922 679 receivable, net Inventories 1,475 1,569 Prepaid expenses and 82 80 other Assets held for sale 1 1 Total current assets 3,219 3,001 Property, plant, and 9,996 9,920 equipment Less: Accumulated (6,992 ) (6,842 ) depreciation Property, plant, and 3,004 3,078 equipment, net Operating lease 282 271 right-of-use assets Goodwill 46 46 Other intangible 2 2 assets, net Investments in 184 160 affiliates Assets held for sale, — 21 non-current Restricted cash and restricted cash 62 52 equivalents Other assets 494 751 Total assets $ 7,293 $ 7,382 Liabilities Current liabilities: Accounts payable $ 995 $ 954 Compensation and other 87 96 employee-related cost Short-term and current maturities of 50 42 long-term debt Current environmental 116 88 remediation Other accrued 529 506 liabilities Total current 1,777 1,686 liabilities Long-term debt, net 3,783 4,099 Operating lease 192 191 liabilities Long-term environmental 689 530 remediation Deferred income taxes 65 37 Other liabilities 631 588 Total liabilities 7,137 7,131 Commitments and contingent liabilities Equity Common stock (par value $0.01 per share; 810,000,000 shares authorized; 199,333,095 shares issued and 150,519,801 shares 2 2 outstanding at September 30, 2026; 198,720,786 shares issued and 149,893,993 shares outstanding at December 31, 2025) Treasury stock, at cost (48,813,294 shares at September (1,801 ) (1,802 ) 30, 2026 and 48,826,793 at December 31, 2025) Additional paid-in 1,092 1,074 capital Retained earnings 1,073 1,220 Accumulated other (211 ) (244 ) comprehensive loss Total Chemours 155 250 stockholders’ equity Non-controlling 1 1 interests Total equity 156 251 Total liabilities and $ 7,293 $ 7,382 equity
The Chemours Company Consolidated Statements of Cash Flows (Unaudited) 1 (Dollars in millions)
Nine Months Ended Cash flows from September 30, operating activities 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net loss $ (107 ) $ (338 ) Adjustments to reconcile net loss to cash provided by operating activities: Depreciation and 239 259 amortization Gain on sales of (316 ) (8 ) assets and businesses Equity in earnings of (20 ) (23 ) affiliates, net Loss on extinguishment 11 — of debt Amortization of debt issuance costs and 8 9 issue discounts Deferred tax provision 228 82 Asset-related charges 1 27 Stock-based 18 17 compensation expense Net periodic pension (2 ) (1 ) income Defined benefit plan (1 ) (2 ) contributions Other operating charges and credits, (4 ) 19 net Decrease (increase) in operating assets: Accounts and notes (223 ) (163 ) receivable, net Inventories and other current operating 76 (76 ) assets Other non-current 65 70 operating assets (Decrease) increase in operating liabilities: Accounts payable 32 (79 ) Other current 59 92 operating liabilities Other non-current 199 242 operating liabilities Cash provided by 263 127 operating activities Cash flows from investing activities Purchases of property, plant, and (144 ) (168 ) equipment Proceeds from life 1 — insurance policies Proceeds from sales of assets and 342 7 businesses Foreign exchange contract settlements, (8 ) (3 ) net Other investing (3 ) 1 activities Cash provided by (used for) investing 188 (163 ) activities Cash flows from financing activities Proceeds from issuance 700 95 of debt Debt repayments (1,028 ) (119 ) Payments on finance (8 ) (12 ) leases Payments of debt (10 ) (4 ) issuance cost Proceeds from supplier 53 64 financing program Payments to supplier (51 ) (70 ) financing program Proceeds from exercised stock 3 — options, net Payments related to tax withholdings on (2 ) (1 ) vested stock awards Payments of dividends to the Company's (39 ) (63 ) common shareholders Debt extinguishment (6 ) — payments Other financing 17 21 activities Cash used for (371 ) (89 ) financing activities Effect of exchange rate changes on cash, cash equivalents, (3 ) 27 restricted cash and restricted cash equivalents Increase (decrease) in cash, cash equivalents, 77 (98 ) restricted cash and restricted cash equivalents Cash, cash equivalents, restricted cash 724 763 and restricted cash equivalents at January 1, Cash, cash equivalents, restricted cash $ 801 $ 665 and restricted cash equivalents at September 30, Supplemental cash flows information Non-cash investing and financing activities: Purchases of property, plant, and $ 40 $ 28 equipment included in accounts payable
The Chemours Company Segment Financial and Operating Data (Unaudited) (Dollars in millions)
The Chemours Company Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited) (Dollars in millions) GAAP Net Loss Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio Reconciliation 1 Adjusted earnings before interest, taxes, depreciation, and amortization (“Adjusted EBITDA”) is defined as income (loss) before income taxes, excluding the following items: interest expense, depreciation, and amortization; non-operating pension and other post-retirement employee benefit costs, which represents the components of net periodic pension costs excluding the service cost component; exchange (gains) losses included in other income (expense), net; restructuring, asset- related, and other charges; (gains) losses on sales of businesses or assets; and, other items not considered indicative of the Company’s ongoing operational performance and expected to occur infrequently, including certain litigation related and environmental charges and Qualified Spend reimbursable by DuPont and/or Corteva as part of the Company's cost-sharing agreement under the terms of the MOU that were previously excluded from Adjusted EBITDA. Adjusted Net Income is defined as net income (loss) attributable to Chemours, adjusted for items excluded from Adjusted EBITDA, except interest expense, depreciation, amortization, and certain provision for (benefit from) income tax amounts. Net Leverage Ratio is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by Adjusted EBITDA.
GAAP Net Loss Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation
GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio Reconciliation (Continued)1 For the twelve months ended September 30, 2026, restructuring, asset-related and other charges primarily includes employee separation charges related to the 2026 Restructuring Program as well as charges related to our decision to exit our SPS Capstone TM business. For the twelve months ended September 30, 2025, restructuring, asset-related and other charges primarily include charges related to our decision to exit our SPS Capstone TM business and the 2024 Restructuring Program. See "Note 4 –Restructuring, Asset-Related and Other Charges" that will be included in the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 for further details.
For the twelve months ended September 30, 2026, loss on extinguishments of debt reflects costs associated with early redemption of the 2027 senior unsecured notes and partial early redemptions of our 2028 tranche B-3 euro term loan during the second and third quarter of 2026. See "Note 15 - Debt" that will be included in the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 for further details.
For the twelve months ended September 30, 2026, gain on sales of assets and businesses, net includes a gain on sale of $316 million, related to parcels of land at the Company's former manufacturing site in Kuan Yin, Taiwan. See "Note 10 - Property, Plant, and Equipment, Net” that will be included in the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 for further details.
For the twelve months ended September 30, 2026, transaction costs include $4 million of costs associated with the Senior Secured Credit Facilities. See "Note 15 - Debt" that will be included in the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 for further details.
Qualified spend recovery represents costs and expenses that were previously excluded from Adjusted EBITDA, reimbursable by DuPont and/or Corteva as part of our cost-sharing agreement under the terms of the MOU which will be discussed in further detail in "Note 17 – Commitments and Contingent Liabilities" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.
Litigation-related (income) charges, net, pertain to certain litigation settlements and reserves established, PFOA drinking water treatment accruals, and other related legal fees. For the twelve months ended September 30, 2026 and September 30, 2025, litigation-related charges includes $110 million and $287 million related to PFOA and PFAS matters, respectively. See "Note 17 – Commitments and Contingent Liabilities" that will be included in the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 for further details.
Environmental charges pertain to management’s assessment of estimated liabilities associated with certain remediation expenses at various sites. For the twelve months ended September 30, 2026, environmental charges primarily include changes to remediation reserves related to the preliminary Consent Decree entered into with the Environmental Protection Agency, ("EPA"), as well as the West Virginia Department of Environmental Protection ("WVDEP") during 2026. For the twelve months ended September 30, 2025, environmental charges primarily include changes to remediation reserves at the four sites covered by the New Jersey settlement agreement and off-site remediation costs at Dordrecht Works. See "Note 17 – Commitments and Contingent Liabilities" that will be included in the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 for further details.
Adjustments made to income taxes relate to the removal of certain discrete income tax impacts within our provision for income taxes to enhance comparability between periods. This includes $208 million and $153 million related to the recognition of valuation allowances against certain U.S. federal and state deferred tax assets for the twelve months ended September 30, 2026, and September 30, 2025, respectively. During the second quarter of 2026, the Company concluded that a full valuation allowance was required on its U.S. federal and state net deferred tax assets. This conclusion was driven by multiple environmental and legal reserves recorded and the impact of these charges on the Company's long-term forecast of U.S. taxable income used in determining the realizability of U.S. deferred tax assets. This included significant legal and environmental reserves related to the announced settlement with the EPA and WVDEP as well as litigation matters in North Carolina. During the second quarter of 2025, the Company had established a partial valuation allowance on certain of its U.S. federal and state net deferred tax assets, primarily related to 163(j) interest carryforward deferred tax assets. This was driven by the environmental and legal reserves recorded related to the announced settlement with the State of New Jersey. Due to the long period by which these legal and environmental matters settle, which are for 15 years or longer, the related pre-tax charges affect projected future U.S. earnings and management's assessment of the realizability of certain deferred tax assets over a significant period. These valuation allowance adjustments are attributable to discrete legal and environmental events and the related reassessment of deferred tax asset realizability, rather than the Company's ongoing core operating performance. Because these valuation allowance adjustments significantly impact current reported income tax expense and reduce comparability across reporting periods, management believes excluding these impacts provides a more meaningful comparison of underlying operating performance between periods. While future valuation allowance adjustments may occur as facts and circumstances change, the adjustments recognized in each period reflect specific assessments based on the conditions existing at that time. See "Note 6 – Income Taxes" that will be included in the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, for further details.
The income tax impacts included in this caption are determined using the applicable rates in the taxing jurisdictions in which income or expense occurred for each of the reconciling items and represent both current and deferred income tax expense or benefit based on the nature of the non-GAAP financial measure.
For the twelve months ended September 30, 2025, accelerated depreciation charges of $23 million, incurred as part of our decision to exit our SPS Capstone TM business are included within the "Restructuring, asset-related and other charges" caption above, and therefore are not included as separate adjustment within this caption.
Net Leverage Ratio calculated using GAAP measures is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by income (loss) before income taxes. Net Leverage Ratio calculated using non-GAAP measures is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by Adjusted EBITDA. The Chemours Company Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except per share amounts) GAAP Earnings per Share to Adjusted Earnings per Share Reconciliation (1) (2) Adjusted earnings per share (“Adjusted EPS”) is calculated by dividing Adjusted Net Income by the weighted-average number of common shares outstanding. Diluted Adjusted EPS accounts for the dilutive impact of stock-based compensation awards, which include unvested restricted shares. Diluted Adjusted EPS considers the impact of potentially-dilutive securities, except in periods in which there is a loss because the inclusion of the potentially-dilutive securities would have an anti-dilutive effect.
(1) In periods where the Company incurs a net loss, the impact of potentially dilutive securities is excluded from the calculation of EPS under U.S. GAAP, as their inclusion would have an anti-dilutive effect. As such, with respect to the U.S. GAAP measure of diluted EPS, the impact of potentially dilutive securities is excluded from our calculation for the nine months ended September 30, 2026 and 2025, and the three months ended June 30, 2026. With respect to the non-GAAP measure of adjusted diluted EPS, the impact of potentially dilutive securities is included in our calculation for the three and nine months ended September 30, 2026 and 2025, and the three months ended June 30, 2026 as Adjusted Net Income was in a net income position. (2) Figures may not recalculate exactly due to rounding. Basic and diluted earnings (loss) per share are calculated based on unrounded numbers.
The Chemours Company Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except per share amounts) GAAP Cash Flow Provided by Operating Activities to Free Cash Flows and Free Cash Flow Conversion Reconciliation (1) Free Cash Flows is defined as cash flows provided by (used for) operating activities, less purchases of property, plant and equipment as shown in the consolidated statements of cash flows. Free Cash Flow Conversion is calculated as the percentage of Free Cash Flows to Adjusted EBITDA.
(1) Includes the receipt of $150 million related to the PFAS Insurance Proceeds MOU, in connection with the finalization of the JCO with the State of New Jersey, partially offset by approximately $100 million in related settlement payments in Q3 2026. See "Note 17 - Commitments and Contingent Liabilities" to the Interim Consolidated Financial Statements that will be included in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 for further details. 2026 Estimated GAAP Cash Flow Provided by Operating Activities to Estimated Free Cash Flows and Estimated Free Cash Flow Conversion Reconciliation (1) (2) Free Cash Flows is defined as cash flows provided by operating activities, less purchases of property, plant and equipment as shown in the consolidated statements of cash flows. Free Cash Flow Conversion is calculated as the percentage of Free Cash Flows to Adjusted EBITDA.
(1) Cash flows provided by operating activities is inclusive of the anticipated $30 million cash taxes associated with the sale of the Kuan Yin site. (2) Includes the receipt of $150 million in restricted cash related to the PFAS Insurance Proceeds MOU, in connection with the finalization of the JCO with the State of New Jersey, partially offset by approximately $100 million in related settlement payments in the year.
2026 Estimated GAAP Net Loss Attributable to Chemours to Estimated Adjusted Net Income and Estimated Adjusted EBITDA Reconciliation (1)
(Estimated) Year Ending December 31, 2026 ────────────────────────────────────────────────────────────────────────────── Low High Net loss attributable $ (100 ) $ (90 ) to Chemours Restructuring, transaction, and other 210 210 costs, net (2) Adjusted Net Income 110 120 Interest expense, net 275 280 Depreciation and 320 320 amortization All remaining provision 70 80 for income taxes Adjusted EBITDA $ 775 $ 800
(1) The Company's estimates reflect its current visibility and expectations based on market factors, such as currency movements, macro-economic factors, and end-market demand. Actual results could differ materially from these estimates. (2) Restructuring, transaction, and other costs, net includes all reconciling items from net loss attributable to Chemours to Adjusted Net Income, including income taxes relating to reconciling items and adjustments made to income taxes for the removal of certain discrete income tax impacts.
Full text with the tables
EXHIBIT 99.1
The Chemours Company Reports Third Quarter Results
Wilmington, Del.,November 2, 2026 – The Chemours Company (“Chemours” or “the
Company”) (NYSE: CC), a global chemistry company with leading market positions
in Thermal & Specialized Solutions (“TSS”), Titanium Technologies (“TT”), and
Advanced Performance Materials (“APM”), today announced its financial results
for the third quarter 2026.
Key Third Quarter 2026 Results & Recent Highlights1
Net Sales of $1.5 billion, up slightly from the prior-year quarter, reflecting
an approximately 10% year-over-year pricing increase in TT and 26% year-over-
year growth in APM Performance Solutions.
Net Income attributable to Chemours of $196 million, or $1.29 per diluted share,
compared with Net Income attributable to Chemours of $46 million, or $0.31 per
diluted share, in the corresponding prior-year quarter.
Adjusted Net Income 2 of $31 million, or $0.21 per diluted share, compared with
Adjusted Net Income of $26 million, or $0.17 per diluted share, in the
corresponding prior-year quarter.
Adjusted EBITDA 2,3 of $200 million, compared with $189 million in the prior-
year quarter, driven by improved pricing in TT and growth in APM Performance
Solutions.
As previously announced, entered into a settlement with the State of North
Carolina and 11 local entities to resolve litigation relating to PFAS and other
historical discharges from Fayetteville Works, as well as claims of PFAS
contamination unrelated to that site, including from the use of AFFF.
Formally launching Chemours’ liquid cooling portfolio, including four two-phase
direct-to-chip and one immersion cooling fluid under the Faizeon™ liquid cooling
brand.
Completed the sale of the Kuan Yin property for total net consideration of ~$340
million, including the remaining land parcel for $56 million of gross proceeds.
“Our third-quarter results demonstrate strong year-over-year performance in TT
and APM, reflecting pricing execution in TiO2and increased demand across
Performance Solutions’ high-value AI infrastructure including data center and
semiconductor end markets,” said Denise Dignam, Chemours President and CEO. “We
also continued to make meaningful progress under our Pathway to Thrive,
including reaching a settlement with the State of North Carolina, driving
operational improvements through the Chemours Business System, and closing the
sale of the final parcel of land associated with our former Kuan Yin property.
While we continue to navigate TSS stationary aftermarket dynamics and a softer
macroeconomic environment, we remain focused on disciplined execution of our
strategic priorities and the factors within our control to drive long-term
returns for shareholders.”
1Certain prior period amounts have been revised to correct for certain
immaterial errors as further described in our Annual Report on Form 10-K for the
year ended December 31, 2025 as well as the 2025 Earnings Presentation.
2Non-GAAP measures, including Adjusted Net Income, Adjusted EPS and Adjusted
EBITDA referred to throughout, principally exclude the impact of recent
litigation settlements for legacy environmental matters and associated fees, in
addition to other unallocated items – please refer to the attached
"Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures
(Unaudited)”.
3Adjusted EBITDA excludes net income attributable to noncontrolling interests,
net interest expense, depreciation and amortization, and all remaining provision
for income taxes from Adjusted Net Income. See the corresponding reconciliation
referenced in footnote #2.
4Restricted cash approximated $103 million of the end of the third quarter of
2026, reflected primarily the PFAS Insurance Escrow and will be further
described in our Quarterly Report on Form 10-Q for the quarter ended September
30, 2026.
EXHIBIT 99.1
Total Chemours
Q3 2026 Q3 2025 Y-o-Y % ∆ Q2 2026 Q-o-Q % ∆
Net Sales (millions) $1,540 $1,495 3% $1,591 -3%
Net Income (Loss)
attributable to $196 $46 326% -$274 172%
Chemours (millions)
Earnings (Loss) Per Share2 $1.29 $0.31 316% -$1.81 171%
Adjusted Net Income $31 $26 19% $64 -52%
Adjusted EPS $0.21 $0.17 24% $0.42 -50%
Adjusted EBITDA (millions) $200 $189 6% $247 -19%
Third quarter 2026 Net Sales were approximately $1.5 billion, an increase of
approximately 3% compared with the prior-year quarter. The year-over-year
increase in Net Sales was driven by a 5% increase in pricing, partially offset
by a 2% decrease in volumes and a slight currency headwind. The pricing increase
was primarily driven by previously announced price actions in TT, complemented
by a favorable mix shift toward APM Performance Solutions. Lower year-over-year
volumes primarily reflected anticipated lower North American stationary AC
aftermarket sales of TSS Opteon TM blends compared with elevated demand in the
prior-year quarter. Third quarter 2026 Net Income attributable to Chemours was
$196 million, or $1.29 per diluted share, compared with $46 million, or $0.31
per diluted share, in the prior-year quarter. Current-year third-quarter Net
Income included the receipt of $150 million related to the PFAS insurance
proceeds MOU that was executed in connection with the finalization of the
judicial consent order ("JCO") with the State of New Jersey. This was presented
as a reduction to Selling, general, and administrative expense. Third quarter
Adjusted Net Income increased 19% compared with the prior-year quarter, aligned
with trends in Adjusted EBITDA as highlighted below. Adjusted EBITDA for the
third quarter of 2026 was $200 million, compared with $189 million in the prior-
year quarter. The increase was driven by pricing momentum in TT and a favorable
mix shift toward APM Performance Solutions, partially offset by lower TSS
volumes associated with the North American stationary AC aftermarket dynamics
noted above and higher costs across each business.
2On a diluted earnings per share basis.
EXHIBIT 99.1
Thermal & Specialized Solutions
Q3 2026 Q3 2025 Y-o-Y % ∆ Q2 2026 Q-o-Q % ∆
Net Sales (millions) $510 $560 -9% $591 -14%
Opteon™ Refrigerants $287 $368 -22% $337 -15%
Freon™ Refrigerants $100 $94 6% $150 -33%
Foam, Propellants & Other $123 $98 26% $104 18%
(FP&O)
Adjusted EBITDA (millions) $136 $194 -30% $213 -36%
Adjusted EBITDA Margin 27% 35% (8) ppts 36% (9) ppts
TSS segment third quarter 2026 Net Sales were $510 million, a decrease of 9%
compared with the prior-year quarter, driven by a 9% decrease in volumes and a
slight decrease in price. The decrease in volumes was primarily attributable to
lower North American stationary AC aftermarket sales of TSS Opteon™ blends
compared with elevated demand in the prior-year quarter, which benefited from
the initial aftermarket channel fill associated with the stationary AC
technology transition under the U.S. AIM Act. Adjusted EBITDA for the quarter
decreased 30% to $136 million, while Adjusted EBITDA Margin decreased eight
points to 27%. The decrease in Adjusted EBITDA was primarily driven by the lower
Opteon TM stationary aftermarket sales noted above and higher costs incurred
during the period. Sequentially, TSS Net Sales decreased 14%, driven by lower
volumes associated with seasonal demand trends in the North American stationary
AC aftermarket, as well as a slight currency headwind, partially offset by
pricing. Titanium Technologies
Q3 2026 Q3 2025 Y-o-Y % ∆ Q2 2026 Q-o-Q % ∆
Net Sales (millions) $680 $612 11% $661 3%
TiO2 Pigment $650 $591 10% $639 2%
Minerals $30 $21 43% $22 36%
Adjusted EBITDA (millions) $85 $25 240% $48 77%
Adjusted EBITDA Margin 13% 4% 9 ppts 7% 6 ppts
TT segment third quarter 2026 Net Sales were $680 million, an 11% increase
compared with the prior-year quarter. The increase was driven by a 10% increase
in global pricing and a 1% increase in global volumes, partially offset by a
slight currency headwind. Pricing increased across all regions in connection
with recent pricing announcements, while global volume growth reflected strength
in North America, Latin America, and APAC excluding China that more than offset
lower volumes across EMEA and China. TT segment third quarter 2026 Adjusted
EBITDA increased to $85 million from $25 million in the prior-year quarter and
Adjusted EBITDA Margin increased by nine points to 13%. The increase in Adjusted
EBITDA was primarily driven by the global pricing strength noted above and
higher volumes, partially offset by modest cost inflation. Sequentially, TT
segment third quarter 2026 Net Sales increased 3%, driven by a 4% increase in
price, reflecting continued execution of recent TiO 2 pricing announcements,
partially offset by a 1% decrease in global volumes and a slight currency
headwind.
2On a diluted earnings per share basis.
EXHIBIT 99.1
Advanced Performance Materials
Q3 2026 Q3 2025 Y-o-Y % ∆ Q2 2026 Q-o-Q % ∆
Net Sales (millions) $337 $311 8% $326 3%
Advanced Materials $184 $190 -3% $184 0%
Performance Solutions $153 $121 26% $142 8%
Adjusted EBITDA (millions) $24 $14 71% $26 -8%
Adjusted EBITDA Margin 7% 5% 2 ppts 8% (1) ppts
APM segment third quarter 2026 Net Sales were $337 million, an 8% increase
compared with the prior-year quarter. The increase was driven by a 6% increase
in price and a 2% increase in volume, partially offset by a slight currency
headwind. Performance Solutions Net Sales increased 26%, reflecting continued
order book strength and momentum in high-value specialty products serving data
center and semiconductor end markets. APM segment third quarter 2026 Adjusted
EBITDA increased 71% to $24 million compared with the prior-year quarter, while
Adjusted EBITDA Margin increased two points to 7%. The increase in Adjusted
EBITDA was primarily driven by a favorable mix shift toward higher-value
Performance Solutions products serving data center and semiconductor end
markets, partially offset by higher costs incurred during the period.
Sequentially, APM segment third quarter 2026 Net Sales increased approximately
3%, driven by a 2% increase in price and a 1% increase in volume. Performance
Solutions Net Sales increased 8%, reflecting continued order book strength and
momentum in high-value specialty products serving data center and semiconductor
end markets.
EXHIBIT 99.1
Other Non-Reportable Segment
The Performance Chemicals and Intermediates business in the Company’s Other Non-
Reportable Segment had Net Sales and Adjusted EBITDA for the third quarter 2026
of $13 million and $1 million, respectively.
Corporate Expenses
Corporate Expenses were $46 million in the third quarter of 2026, an increase of
approximately $1 million compared with the prior-year quarter.
Liquidity and Capital Allocation
As of September 30, 2026, consolidated gross debt was $3.9 billion. Debt, net of
$698 million in unrestricted4cash and cash equivalents, was $3.2 billion,
resulting in a Net Leverage ratio of approximately 4.3x on a trailing twelve-
month Adjusted EBITDA basis. Total liquidity was $1.7 billion, composed of $698
million in unrestrictedcash and cash equivalents and $953 million of revolving
credit facility capacity, net of outstanding letters of credit.
Operating cash flows for the third quarter of 2026 were $149 million, which
includes the aforementioned receipt of $150 million in restricted cash related
to the PFAS insurance proceeds MOU in connection with the finalization of the
JCO with the State of New Jersey, partially offset by an approximately $100
million use of restricted cash to fund settlement payments associated with the
2025 settlement with the State of New Jersey and approximately $25 million of
taxes related to the property sale in Kuan Yin. This is compared with $146
million of operating cash flows in the prior-year quarter.
Capital expenditures for the third quarter of 2026 amounted to $51 million, an
increase compared with $41 million in the prior-year quarter.
Free Cash Flows for the third quarter of 2026 were $98 million, compared with
$105 million in the third quarter of 2025.
3Restricted cash was $103 million at the end of the third quarter of 2026,
primarily reflecting PFAS Insurance proceeds MOU escrow recorded during the
quarter as further described in our Quarterly Report on Form 10-Q for the
quarter ended September 30, 2026.
EXHIBIT 99.1
Fourth Quarter 2026 Outlook
In the fourth quarter, the Company expects consolidated Net Sales to decrease in
the range of 5% to 10%, sequentially, driven by seasonality in TSS and TT, with
consolidated Adjusted EBITDA expected to range between $160 million and $185
million. Corporate Expenses are expected to be approximately $40 million to $45
million. The Company also anticipates capital expenditures to be between $75
million and $85 million, with positive Free Cash Flows.
TSS expects Net Sales will sequentially decrease in the high-teens to low-
twenties percentage range, driven by traditional seasonal patterns related to
the North American cooling season. Adjusted EBITDA is expected to be between
$105 million and $115 million.
TT expects a sequential Net Sales decrease in the high single-digit to low-teens
percentage range, driven by seasonality. Adjusted EBITDA is expected to range
between $60 million and $65 million.
APM expects a sequential Net Sales increase in the low-to-mid teens percentage
range, driven by order book strength for Performance Solutions products and
certain customer contractual obligations benefiting the fourth quarter. Adjusted
EBITDA for APM is expected to be between $40 million and $45 million.
Full Year 2026 Outlook
The Company expects 2026 Net Sales to grow approximately 2% over 2025, with
Adjusted EBITDA between $775 million and $800 million. Capital expenditures are
anticipated to be between $220 million and $230 million, with overall Free Cash
Flow Conversion above 15%, which includes receipt of $150 million in restricted
cash related to the PFAS insurance proceeds MOU in connection with the
finalization of the JCO with the State of New Jersey, partially offset by legal
settlement payments in the year related to the finalization of the JCO with the
State of New Jersey and the announced settlement with the State of North
Carolina during the third quarter of 2026 as well as the taxes associated with
the Kuan Yin property sale now complete. The Company now anticipates achieving a
Net Leverage ratio below 4.2x in 2026.
EXHIBIT 99.1
Conference Call
As previously announced, Chemours will hold a conference call and webcast on
November 3, 2026, at 8:00 a.m. Eastern Standard Time. The webcast and materials
can be accessed by visiting theEvents & Presentationspage of Chemours’ investor
website,investors.chemours.com. A webcast replay of the conference call will be
available on Chemours’ investor website.
About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and
specialty chemical products for markets, including coatings, plastics,
refrigeration and air conditioning, transportation, semiconductor and advanced
electronics, general industrial, and oil and gas. Through our three businesses –
Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance
Materials – we deliver application expertise and chemistry-based innovations
that solve customers’ biggest challenges. Our flagship products are sold under
prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™,
and Krytox™. Headquartered in Wilmington, Delaware, and listed on the NYSE under
the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing
sites and serves approximately 2,400 customers in approximately 110 countries.
For more information, visitchemours.comor follow us onLinkedIn.
Non-GAAP Financial Measures
We prepare our financial statements in accordance with Generally Accepted
Accounting Principles (GAAP). Within this press release, we may make reference
to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Free Cash Flows, Free
Cash Flow Conversion, Total Debt Principal, Net and Net Leverage Ratio which are
non-GAAP financial measures. The Company includes these non-GAAP financial
measures because management believes they are useful to investors in that they
provide for greater transparency with respect to supplemental information used
by management in its financial and operational decision making. Management uses
Adjusted Net Income, Adjusted EPS and Adjusted EBITDA, which adjust for (i)
certain non-cash items, (ii) certain items we believe are not indicative of
ongoing operating performance, or (iii) certain nonrecurring, unusual or
infrequent items to evaluate the Company's performance in order to have
comparable financial results to analyze changes in our underlying business from
period to period. Additionally, Free Cash Flows, Free Cash Flow Conversion,
Total Debt Principal, Net and Net Leverage Ratio are utilized as liquidity
measures to assess the cash generation of our businesses and ongoing liquidity
position.
Accordingly, the Company believes the presentation of these non-GAAP financial
measures, when used in conjunction with GAAP financial measures, is a useful
financial analysis tool that can assist investors in assessing the Company's
operating performance and underlying prospects. This analysis should not be
considered in isolation or as a substitute for analysis of our results as
reported under GAAP. This analysis, as well as the other information in this
press release, should be read in conjunction with the Company's financial
statements and footnotes contained in the documents that the Company files with
the U.S. Securities and Exchange Commission. The non-GAAP financial measures
used by the Company in this press release may be different from the methods used
by other companies. The Company does not provide a reconciliation of certain
forward-looking non-GAAP financial measures to the most directly comparable GAAP
reported financial measures on a forward-looking basis because it is unable to
predict with reasonable certainty the ultimate outcome of unusual gains and
losses, potential future asset impairments and pending litigation without
unreasonable effort. These items are uncertain, depend on various factors, and
could have a material impact on GAAP reported results for the guidance period.
For more information on the non-GAAP financial measures, please refer to the
attached schedules or the table, "Reconciliation of GAAP Financial Measures to
Non-GAAP Financial Measures (Unaudited)" and materials posted to the Company's
website at investors.chemours.com.
EXHIBIT 99.1
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, which involve risks and uncertainties. Forward-looking
statements provide current expectations of future events based on certain
assumptions and include any statement that does not directly relate to a
historical or current fact. The words "believe," "expect," "will," "anticipate,"
"plan," "estimate," "target," "project" and similar expressions, among others,
generally identify "forward-looking statements," which speak only as of the date
such statements were made. These forward-looking statements may address, among
other things, guidance on Company and segment performance for the fourth quarter
of 2026, the full year 2026 and the Company’s corporate strategy. Forward-
looking statements are based on certain assumptions and expectations of future
events that may not be accurate or realized, such as guidance relying on models
based upon management assumptions regarding future events that are inherently
uncertain. These statements are not guarantees of future performance. Forward-
looking statements also involve risks and uncertainties including the outcome or
resolution of any pending or future environmental liabilities, the commencement,
outcome or resolution of any regulatory inquiry, investigation or proceeding,
the initiation, outcome or settlement of any litigation, our ability to maintain
an effective internal control over financial reporting and disclosure controls
and procedures, changes in environmental regulations in the United States or
other jurisdictions that affect demand for or adoption of our products, changes
in regulations in the United States or other jurisdictions that could impose
tariffs or additional costs on products we either sell or need to purchase,
anticipated future operating and financial performance for our segments
individually and our company as a whole, business plans, prospects, targets,
goals and commitments, capital investments and projects and target capital
expenditures, efforts to resolve outstanding or potential litigation, including
claims related to legacy PFAS liabilities, plans for dividends, sufficiency or
longevity of intellectual property protection, cost reductions or savings
targets, plans to increase profitability and growth, ourability todevelop and
commercialize new products or technologies and obtain necessary regulatory
approvals,our ability to make acquisitions, integrate acquired businesses or
assets into our operations, and achieve anticipated synergies or cost savings,
all of which are subject to substantial risks and uncertainties that could cause
actual results to differ materially from those expressed or implied by such
statements. These statements also may involve risks and uncertainties that are
beyond Chemours' control. Matters outside our control, including general
economic conditions, geopolitical conditions, global conflicts, changes in laws
and regulations in the United States or other jurisdictions in which we operate,
and global health events and weather events, have affected or may affect our
business and operations and may or may continue to hinder our ability to provide
goods and services to customers, cause disruptions in our supply chains such as
through strikes, labor disruptions or other events, adversely affect our
business partners, significantly reduce the demand for our products, adversely
affect the health and welfare of our personnel or cause other unpredictable
events. Additionally, there may be other risks and uncertainties that Chemours
is unable to identify at this time or that Chemours does not currently expect to
have a material impact on its business. Factors that could cause or contribute
to these differences include the risks, uncertainties and other factors
discussed in our filings with the U.S. Securities and Exchange Commission,
including in our forthcoming Quarterly Report on Form 10-Q for the quarter ended
September 30, 2026 and the Annual Report on Form 10-K for the year ended
December 31, 2025. Chemours assumes no obligation to revise or update any
forward-looking statement for any reason, except as required by law.
EXHIBIT 99.1
CONTACTS:
INVESTORSBrandon OntjesVice President, Head of Strategy & Investor
Relations+1.302.773.3309
[email protected]
NEWS MEDIACassie OlszewskiMedia Relations & Reputation
[email protected]
The Chemours Company Consolidated Statements of Operations (Unaudited) 1
(Dollars in millions, except per share amounts)
Three Nine
Mont… Mont…
Ended Ended
Sept… Sept…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 1,540 $ 1,495 $ 4,512 $ 4,478
sal…
Cost
of 1,309 1,262 3,783 3,732
goo…
sold
Gro… 231 233 729 746
pro…
Sel…
gen…
and (25 ) 122 591 669
adm…
exp…
(1)
Res…
and 24 26 77 81
dev…
exp…
Res…
ass…
and 3 4 19 55
oth…
cha…
Tot…
oth… 2 152 687 805
ope…
exp…
Equ…
in
ear… 11 9 28 27
of
aff…
Int…
exp… (69 ) (68 ) (206 ) (201 )
net
Loss
on
ext… — — (11 ) —
of
debt
Oth…
inc… 51 16 347 23
net
Inc…
bef… 222 38 200 (210 )
inc…
tax…
Pro…
for
(be… 26 (8 ) 307 128
fro…
inc…
tax…
Net
inc… 196 46 (107 ) (338 )
(lo…
Les…
Net
inc…
att… — — — 1
to
non…
int…
Net
inc…
(lo… $ 196 $ 46 $ (107 ) $ (339 )
att…
to
Che…
Per
sha…
data
Bas…
ear…
(lo…
per $ 1.29 $ 0.31 $ (0.71 ) $ (2.26 )
sha…
of
com…
sto…
Dil…
ear…
(lo…
per 1.29 0.31 (0.71 ) (2.26 )
sha…
of
com…
sto…
(1) Selling, general, and administrative expense for the three and nine months
ended September 30, 2026 includes $150 million received by the Company related
to the PFAS Insurance proceeds MOU. Further details will be included in "Note 17
- Commitments and Contingent Liabilities" to the Interim Consolidated Financial
Statements in our Quarterly Report on Form 10-Q for the quarter ended September
30, 2026.
The Chemours Company Consolidated Balance Sheets (Unaudited) 1 (Dollars in
millions, except per share amounts)
September 30, 2026 December 31, 2025
──────────────────────────────────────────────────────────────────────────────
Assets
Current assets:
Cash and cash $ 698 $ 670
equivalents
Restricted cash and
restricted cash 41 2
equivalents
Accounts and notes 922 679
receivable, net
Inventories 1,475 1,569
Prepaid expenses and 82 80
other
Assets held for sale 1 1
Total current assets 3,219 3,001
Property, plant, and 9,996 9,920
equipment
Less: Accumulated (6,992 ) (6,842 )
depreciation
Property, plant, and 3,004 3,078
equipment, net
Operating lease 282 271
right-of-use assets
Goodwill 46 46
Other intangible 2 2
assets, net
Investments in 184 160
affiliates
Assets held for sale, — 21
non-current
Restricted cash and
restricted cash 62 52
equivalents
Other assets 494 751
Total assets $ 7,293 $ 7,382
Liabilities
Current liabilities:
Accounts payable $ 995 $ 954
Compensation and
other 87 96
employee-related
cost
Short-term and
current maturities of 50 42
long-term debt
Current environmental 116 88
remediation
Other accrued 529 506
liabilities
Total current 1,777 1,686
liabilities
Long-term debt, net 3,783 4,099
Operating lease 192 191
liabilities
Long-term
environmental 689 530
remediation
Deferred income taxes 65 37
Other liabilities 631 588
Total liabilities 7,137 7,131
Commitments and
contingent
liabilities
Equity
Common stock (par
value $0.01 per
share;
810,000,000 shares
authorized;
199,333,095 shares
issued and
150,519,801 shares 2 2
outstanding at
September 30, 2026;
198,720,786 shares
issued and
149,893,993 shares
outstanding at
December 31, 2025)
Treasury stock, at
cost (48,813,294
shares at September (1,801 ) (1,802 )
30, 2026 and
48,826,793 at
December 31, 2025)
Additional paid-in 1,092 1,074
capital
Retained earnings 1,073 1,220
Accumulated other (211 ) (244 )
comprehensive loss
Total Chemours 155 250
stockholders’ equity
Non-controlling 1 1
interests
Total equity 156 251
Total liabilities and $ 7,293 $ 7,382
equity
The Chemours Company Consolidated Statements of Cash Flows (Unaudited) 1
(Dollars in millions)
Nine Months Ended
Cash flows from September 30,
operating activities 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net loss $ (107 ) $ (338 )
Adjustments to
reconcile net loss to
cash provided by
operating activities:
Depreciation and 239 259
amortization
Gain on sales of (316 ) (8 )
assets and businesses
Equity in earnings of (20 ) (23 )
affiliates, net
Loss on extinguishment 11 —
of debt
Amortization of debt
issuance costs and 8 9
issue discounts
Deferred tax provision 228 82
Asset-related charges 1 27
Stock-based 18 17
compensation expense
Net periodic pension (2 ) (1 )
income
Defined benefit plan (1 ) (2 )
contributions
Other operating
charges and credits, (4 ) 19
net
Decrease (increase) in
operating assets:
Accounts and notes (223 ) (163 )
receivable, net
Inventories and other
current operating 76 (76 )
assets
Other non-current 65 70
operating assets
(Decrease) increase in
operating
liabilities:
Accounts payable 32 (79 )
Other current 59 92
operating liabilities
Other non-current 199 242
operating liabilities
Cash provided by 263 127
operating activities
Cash flows from
investing activities
Purchases of property,
plant, and (144 ) (168 )
equipment
Proceeds from life 1 —
insurance policies
Proceeds from sales of
assets and 342 7
businesses
Foreign exchange
contract settlements, (8 ) (3 )
net
Other investing (3 ) 1
activities
Cash provided by (used
for) investing 188 (163 )
activities
Cash flows from
financing activities
Proceeds from issuance 700 95
of debt
Debt repayments (1,028 ) (119 )
Payments on finance (8 ) (12 )
leases
Payments of debt (10 ) (4 )
issuance cost
Proceeds from supplier 53 64
financing program
Payments to supplier (51 ) (70 )
financing program
Proceeds from
exercised stock 3 —
options,
net
Payments related to
tax withholdings on (2 ) (1 )
vested stock awards
Payments of dividends
to the Company's (39 ) (63 )
common shareholders
Debt extinguishment (6 ) —
payments
Other financing 17 21
activities
Cash used for (371 ) (89 )
financing activities
Effect of exchange
rate changes on cash,
cash equivalents, (3 ) 27
restricted cash and
restricted cash
equivalents
Increase (decrease) in
cash, cash
equivalents, 77 (98 )
restricted cash and
restricted cash
equivalents
Cash, cash
equivalents,
restricted cash 724 763
and restricted cash
equivalents at
January 1,
Cash, cash
equivalents,
restricted cash $ 801 $ 665
and restricted cash
equivalents at
September 30,
Supplemental cash
flows information
Non-cash investing and
financing
activities:
Purchases of property,
plant, and $ 40 $ 28
equipment included in
accounts payable
The Chemours Company Segment Financial and Operating Data (Unaudited) (Dollars
in millions)
S… Th…
N… Mo…
S…
En… Se…
Th…
Mo… In… Ju… In…
En… / 30, /
Se…
30,
20… 20… -D… 20… -D…
T…
& $ 510 $ 560 $ (50 ) $ 591 $ (81 )
S…
S…
T… 680 612 68 661 19
T…
A…
P… 337 311 26 326 11
M…
O…
N… 13 12 1 13 0
S…
T…
N… $ 1,… $ 1,… $ 45 $ 1,… $ (51 )
S…
S… Th…
A… Mo…
E…
En… Se…
Th…
Mo… In… Ju… In…
En… / 30, /
Se…
30,
20… 20… -D… 20… -D…
T…
& $ 136 $ 194 $ (58 ) $ 213 $ (77 )
S…
S…
T… $ 85 $ 25 $ 60 $ 48 $ 37
T…
A…
P… $ 24 $ 14 $ 10 $ 26 $ (2 )
M…
O…
N… $ 1 $ 2 $ (1 ) $ 2 $ (1 )
S…
Q…
C…
in
N…
S…
f…
t…
t…
m…
e… Pe…
S… Se… Pe… Ch…
3… 30, Ch… Due
2… 20… vs. To
──────────────────────────────────────────────────────────────────────────────
Net Se…
Sa… 30, Pr… Vo… Cu… Po…
20…
T… $ 1,… 3 % 5 % (2 )% — % — %
C…
T…
& $ 510 (9 )% — % (9 )% — % — %
S…
S…
T… 680 11 % 10 % 1 % — % — %
T…
A…
P… 337 8 % 6 % 2 % — % — %
M…
O…
N… 13 10 % 6 % 4 % — % — %
S…
Q…
C…
in
N…
S…
f…
t…
t…
m…
e… P…
S… Se… Pe… C…
3… 30, Ch… D…
2… 20… vs. To
──────────────────────────────────────────────────────────────────────────────
Net Ju…
Sa… 30, P… Vo… Cu… P…
20…
T… $ 1,… (3 )% 2 % (5 )% — % — %
C…
T…
& $ 510 (14 )% — % (… )% — % — %
S…
S…
T… 680 3 % 4 % (1 )% — % — %
T…
A…
P… 337 3 % 2 % 1 % — % — %
M…
O…
N… 13 (5 )% (3 )% (2 )% — % — %
S…
The Chemours Company Reconciliation of GAAP Financial Measures to Non-GAAP
Financial Measures (Unaudited) (Dollars in millions) GAAP Net Loss Attributable
to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation GAAP Net
Leverage Ratio to Non-GAAP Net Leverage Ratio Reconciliation 1 Adjusted earnings
before interest, taxes, depreciation, and amortization (“Adjusted EBITDA”) is
defined as income (loss) before income taxes, excluding the following items:
interest expense, depreciation, and amortization; non-operating pension and
other post-retirement employee benefit costs, which represents the components of
net periodic pension costs excluding the service cost component; exchange
(gains) losses included in other income (expense), net; restructuring, asset-
related, and other charges; (gains) losses on sales of businesses or assets;
and, other items not considered indicative of the Company’s ongoing operational
performance and expected to occur infrequently, including certain litigation
related and environmental charges and Qualified Spend reimbursable by DuPont
and/or Corteva as part of the Company's cost-sharing agreement under the terms
of the MOU that were previously excluded from Adjusted EBITDA. Adjusted Net
Income is defined as net income (loss) attributable to Chemours, adjusted for
items excluded from Adjusted EBITDA, except interest expense, depreciation,
amortization, and certain provision for (benefit from) income tax amounts. Net
Leverage Ratio is defined as our total debt principal, net, or our total debt
principal outstanding less unrestricted cash and cash equivalents, divided by
Adjusted EBITDA.
… …
… …
… …
… …
… …
… … …
──────────────────────────────────────────────────────────────────────────────
$ … $ … $ …
$ ) … $ … $ …
) … … …
7 8 …
… … …
— … 1
) … … …
2 6 4
) … … …
… … …
… … …
… … …
… … …
… … …
1 … 1
… … …
… … …
… … …
$ … $ … $ …
$ … $ …
… …
$ … $ …
GAAP Net Loss Attributable to Chemours to Adjusted Net Income and Adjusted
EBITDA Reconciliation
GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio Reconciliation
(Continued)1
For the twelve months ended September 30, 2026, restructuring, asset-related and
other charges primarily includes employee separation charges related to the 2026
Restructuring Program as well as charges related to our decision to exit our SPS
Capstone TM business. For the twelve months ended September 30, 2025,
restructuring, asset-related and other charges primarily include charges related
to our decision to exit our SPS Capstone TM business and the 2024 Restructuring
Program. See "Note 4 –Restructuring, Asset-Related and Other Charges" that will
be included in the Interim Consolidated Financial Statements in our Quarterly
Report on Form 10-Q for the quarter ended September 30, 2026 for further
details.
For the twelve months ended September 30, 2026, loss on extinguishments of debt
reflects costs associated with early redemption of the 2027 senior unsecured
notes and partial early redemptions of our 2028 tranche B-3 euro term loan
during the second and third quarter of 2026. See "Note 15 - Debt" that will be
included in the Interim Consolidated Financial Statements in our Quarterly
Report on Form 10-Q for the quarter ended September 30, 2026 for further
details.
For the twelve months ended September 30, 2026, gain on sales of assets and
businesses, net includes a gain on sale of $316 million, related to parcels of
land at the Company's former manufacturing site in Kuan Yin, Taiwan. See "Note
10 - Property, Plant, and Equipment, Net” that will be included in the Interim
Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the
quarter ended September 30, 2026 for further details.
For the twelve months ended September 30, 2026, transaction costs include $4
million of costs associated with the Senior Secured Credit Facilities. See "Note
15 - Debt" that will be included in the Interim Consolidated Financial
Statements in our Quarterly Report on Form 10-Q for the quarter ended September
30, 2026 for further details.
Qualified spend recovery represents costs and expenses that were previously
excluded from Adjusted EBITDA, reimbursable by DuPont and/or Corteva as part of
our cost-sharing agreement under the terms of the MOU which will be discussed in
further detail in "Note 17 – Commitments and Contingent Liabilities" to the
Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q
for the quarter ended September 30, 2026.
Litigation-related (income) charges, net, pertain to certain litigation
settlements and reserves established, PFOA drinking water treatment accruals,
and other related legal fees. For the twelve months ended September 30, 2026 and
September 30, 2025, litigation-related charges includes $110 million and $287
million related to PFOA and PFAS matters, respectively. See "Note 17 –
Commitments and Contingent Liabilities" that will be included in the Interim
Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the
quarter ended September 30, 2026 for further details.
Environmental charges pertain to management’s assessment of estimated
liabilities associated with certain remediation expenses at various sites. For
the twelve months ended September 30, 2026, environmental charges primarily
include changes to remediation reserves related to the preliminary Consent
Decree entered into with the Environmental Protection Agency, ("EPA"), as well
as the West Virginia Department of Environmental Protection ("WVDEP") during
2026. For the twelve months ended September 30, 2025, environmental charges
primarily include changes to remediation reserves at the four sites covered by
the New Jersey settlement agreement and off-site remediation costs at Dordrecht
Works. See "Note 17 – Commitments and Contingent Liabilities" that will be
included in the Interim Consolidated Financial Statements in our Quarterly
Report on Form 10-Q for the quarter ended September 30, 2026 for further
details.
Adjustments made to income taxes relate to the removal of certain discrete
income tax impacts within our provision for income taxes to enhance
comparability between periods. This includes $208 million and $153 million
related to the recognition of valuation allowances against certain U.S. federal
and state deferred tax assets for the twelve months ended September 30, 2026,
and September 30, 2025, respectively. During the second quarter of 2026, the
Company concluded that a full valuation allowance was required on its U.S.
federal and state net deferred tax assets. This conclusion was driven by
multiple environmental and legal reserves recorded and the impact of these
charges on the Company's long-term forecast of U.S. taxable income used in
determining the realizability of U.S. deferred tax assets. This included
significant legal and environmental reserves related to the announced settlement
with the EPA and WVDEP as well as litigation matters in North Carolina. During
the second quarter of 2025, the Company had established a partial valuation
allowance on certain of its U.S. federal and state net deferred tax assets,
primarily related to 163(j) interest carryforward deferred tax assets. This was
driven by the environmental and legal reserves recorded related to the announced
settlement with the State of New Jersey. Due to the long period by which these
legal and environmental matters settle, which are for 15 years or longer, the
related pre-tax charges affect projected future U.S. earnings and management's
assessment of the realizability of certain deferred tax assets over a
significant period. These valuation allowance adjustments are attributable to
discrete legal and environmental events and the related reassessment of deferred
tax asset realizability, rather than the Company's ongoing core operating
performance. Because these valuation allowance adjustments significantly impact
current reported income tax expense and reduce comparability across reporting
periods, management believes excluding these impacts provides a more meaningful
comparison of underlying operating performance between periods. While future
valuation allowance adjustments may occur as facts and circumstances change, the
adjustments recognized in each period reflect specific assessments based on the
conditions existing at that time. See "Note 6 – Income Taxes" that will be
included in the Interim Consolidated Financial Statements in our Quarterly
Report on Form 10-Q for the quarter ended September 30, 2026, for further
details.
The income tax impacts included in this caption are determined using the
applicable rates in the taxing jurisdictions in which income or expense occurred
for each of the reconciling items and represent both current and deferred income
tax expense or benefit based on the nature of the non-GAAP financial measure.
For the twelve months ended September 30, 2025, accelerated depreciation charges
of $23 million, incurred as part of our decision to exit our SPS Capstone TM
business are included within the "Restructuring, asset-related and other
charges" caption above, and therefore are not included as separate adjustment
within this caption.
Net Leverage Ratio calculated using GAAP measures is defined as our total debt
principal, net, or our total debt principal outstanding less unrestricted cash
and cash equivalents, divided by income (loss) before income taxes. Net Leverage
Ratio calculated using non-GAAP measures is defined as our total debt principal,
net, or our total debt principal outstanding less unrestricted cash and cash
equivalents, divided by Adjusted EBITDA.
The Chemours Company Reconciliation of GAAP Financial Measures to Non-GAAP
Financial Measures (Unaudited) (Dollars in millions, except per share amounts)
GAAP Earnings per Share to Adjusted Earnings per Share Reconciliation (1) (2)
Adjusted earnings per share (“Adjusted EPS”) is calculated by dividing Adjusted
Net Income by the weighted-average number of common shares outstanding. Diluted
Adjusted EPS accounts for the dilutive impact of stock-based compensation
awards, which include unvested restricted shares. Diluted Adjusted EPS considers
the impact of potentially-dilutive securities, except in periods in which there
is a loss because the inclusion of the potentially-dilutive securities would
have an anti-dilutive effect.
Thr… Nine
Mon… Mont…
End… Ended
Sep… June Sept…
30, 30, 30,
Nu… 2026 2025 2026 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net
In…
(L… $ 196 $ 46 $ -274 $ -107 $ -339
at…
to
Ch…
Ad…
Net 31 26 64 102 137
In…
De…
We…
nu…
of
co… 151… 150… 151… 151… 150,…
sh…
ou…
-
ba…
Di…
ef…
of
the
Co… 578… 461… 1,5… 995… 406,…
em…
co…
pl…
(1)
We…
nu…
of
co…
sh… 151… 150… 152… 152… 150,…
ou…
-
di…
(1)
Ba…
ea…
(l…
per
sh… $ 1.29 $ 0.31 $ -1.… $ -0.… $ -2.26
of
co…
st…
(2)
Di…
ea…
(l…
per
sh… 1.29 0.31 -1.… -0.… -2.26
of
co…
st…
(1)
(2)
Ad…
ba…
ea…
per
sh… 0.21 0.17 0.42 0.68 0.91
of
co…
st…
(2)
Ad…
di…
ea…
per
sh… 0.21 0.17 0.42 0.67 0.91
of
co…
st…
(1)
(2)
(1) In periods where the Company incurs a net loss, the impact of potentially
dilutive securities is excluded from the calculation of EPS under U.S. GAAP, as
their inclusion would have an anti-dilutive effect. As such, with respect to the
U.S. GAAP measure of diluted EPS, the impact of potentially dilutive securities
is excluded from our calculation for the nine months ended September 30, 2026
and 2025, and the three months ended June 30, 2026. With respect to the non-GAAP
measure of adjusted diluted EPS, the impact of potentially dilutive securities
is included in our calculation for the three and nine months ended September 30,
2026 and 2025, and the three months ended June 30, 2026 as Adjusted Net Income
was in a net income position. (2) Figures may not recalculate exactly due to
rounding. Basic and diluted earnings (loss) per share are calculated based on
unrounded numbers.
The Chemours Company Reconciliation of GAAP Financial Measures to Non-GAAP
Financial Measures (Unaudited) (Dollars in millions, except per share amounts)
GAAP Cash Flow Provided by Operating Activities to Free Cash Flows and Free Cash
Flow Conversion Reconciliation (1) Free Cash Flows is defined as cash flows
provided by (used for) operating activities, less purchases of property, plant
and equipment as shown in the consolidated statements of cash flows. Free Cash
Flow Conversion is calculated as the percentage of Free Cash Flows to Adjusted
EBITDA.
T… N…
M… M…
E… E…
S… J… S…
3… 3… 3…
2… 2… 2… 2… 2…
──────────────────────────────────────────────────────────────────────────────
…
…
…
… $ 1… $ 1… $ 1… $ 2… $ 1…
…
…
…
…
…
…
…
… (… ) (… ) (… ) (… ) (… )
…
…
…
…
… $ 98 $ 1… $ 1… $ 1… $ (… )
…
… 2… 1… 2… 6… 6…
…
…
… 49 % 56 % 46 % 19 % (7 …
…
…
(1) Includes the receipt of $150 million related to the PFAS Insurance Proceeds
MOU, in connection with the finalization of the JCO with the State of New
Jersey, partially offset by approximately $100 million in related settlement
payments in Q3 2026. See "Note 17 - Commitments and Contingent Liabilities" to
the Interim Consolidated Financial Statements that will be included in our
Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 for
further details. 2026 Estimated GAAP Cash Flow Provided by Operating Activities
to Estimated Free Cash Flows and Estimated Free Cash Flow Conversion
Reconciliation (1) (2) Free Cash Flows is defined as cash flows provided by
operating activities, less purchases of property, plant and equipment as shown
in the consolidated statements of cash flows. Free Cash Flow Conversion is
calculated as the percentage of Free Cash Flows to Adjusted EBITDA.
Estimated
Year Ended December
31, 2026
──────────────────────────────────────────────────────────────────────────────
Low High
Cash flows provided
by operating $ 340 $ 390
activities
Less:
Purchases of (220 ) (230 )
property, plant, and
equipment
Free Cash Flows $ 120 $ 160
Adjusted EBITDA 775 800
Free Cash Flow 15 % 20 %
Conversion
(1) Cash flows provided by operating activities is inclusive of the anticipated
$30 million cash taxes associated with the sale of the Kuan Yin site. (2)
Includes the receipt of $150 million in restricted cash related to the PFAS
Insurance Proceeds MOU, in connection with the finalization of the JCO with the
State of New Jersey, partially offset by approximately $100 million in related
settlement payments in the year.
2026 Estimated GAAP Net Loss Attributable to Chemours to Estimated Adjusted Net
Income and Estimated Adjusted EBITDA Reconciliation (1)
(Estimated)
Year Ending December 31,
2026
──────────────────────────────────────────────────────────────────────────────
Low High
Net loss attributable $ (100 ) $ (90 )
to Chemours
Restructuring,
transaction, and other 210 210
costs, net (2)
Adjusted Net Income 110 120
Interest expense, net 275 280
Depreciation and 320 320
amortization
All remaining provision 70 80
for income taxes
Adjusted EBITDA $ 775 $ 800
(1) The Company's estimates reflect its current visibility and expectations
based on market factors, such as currency movements, macro-economic factors, and
end-market demand. Actual results could differ materially from these estimates.
(2) Restructuring, transaction, and other costs, net includes all reconciling
items from net loss attributable to Chemours to Adjusted Net Income, including
income taxes relating to reconciling items and adjustments made to income taxes
for the removal of certain discrete income tax impacts.